ASX - By Stock
|
NEU |
Re:
Ann: P2 trial shows significant improvements in Phelan-McDermid
|
|
TripAces
|
210 |
88K |
12 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
210
|
88K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
1.0K |
543K |
13 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
1.0K
|
543K
|
13
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
1.0K |
543K |
5 |
29/05/24 |
29/05/24 |
ASX - By Stock
|
1.0K
|
543K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins
|
|
TripAces
|
160 |
81K |
25 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
160
|
81K
|
25
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins
|
|
TripAces
|
160 |
81K |
23 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
160
|
81K
|
23
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins
|
|
TripAces
|
160 |
81K |
12 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
160
|
81K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.8M |
16 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
10K
|
4.8M
|
16
|
|
ASX - By Stock
|
BOT |
Re:
BOT - Post Approval Takeover Predictions
|
|
TripAces
|
65 |
28K |
42 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
65
|
28K
|
42
|
|
ASX - By Stock
|
NEU |
AGM
|
|
TripAces
|
10 |
6.1K |
29 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
10
|
6.1K
|
29
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Chairman's Address at 2019 Annual Meeting of Shareholders
|
|
TripAces
|
68 |
36K |
12 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
68
|
36K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Investor presentation, 15 May 2024
|
|
TripAces
|
34 |
18K |
27 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
34
|
18K
|
27
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
1.0K |
543K |
18 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
1.0K
|
543K
|
18
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.8M |
16 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
10K
|
4.8M
|
16
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.8M |
8 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
10K
|
4.8M
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
44 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
605
|
273K
|
44
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.8M |
2 |
10/05/24 |
10/05/24 |
ASX - By Stock
|
10K
|
4.8M
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
5 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
605
|
273K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
1 |
09/05/24 |
09/05/24 |
ASX - By Stock
|
605
|
273K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.8M |
6 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
10K
|
4.8M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
0 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
605
|
273K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
11 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
605
|
273K
|
11
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
2 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
605
|
273K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
6 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
605
|
273K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Annual Report to shareholders
|
|
TripAces
|
194 |
78K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
194
|
78K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Annual Report to shareholders
|
|
TripAces
|
194 |
78K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
194
|
78K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Kidney Disease Drug Candidate Progressing to Human Trials
|
|
TripAces
|
28 |
10K |
6 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
28
|
10K
|
6
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Kidney Disease Drug Candidate Progressing to Human Trials
|
|
TripAces
|
28 |
10K |
34 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
28
|
10K
|
34
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.8M |
1 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
10K
|
4.8M
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.8M |
6 |
21/04/24 |
21/04/24 |
ASX - By Stock
|
10K
|
4.8M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.8M |
19 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
10K
|
4.8M
|
19
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
15 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
605
|
273K
|
15
|
|
ASX - By Stock
|
NEU |
Re:
Upcoming Phase 2 Trial Announcement Dates
|
|
TripAces
|
7 |
3.9K |
2 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
7
|
3.9K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Results webinar
|
|
TripAces
|
130 |
64K |
18 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
130
|
64K
|
18
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Results webinar
|
|
TripAces
|
130 |
64K |
1 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
130
|
64K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Results webinar
|
|
TripAces
|
130 |
64K |
8 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
130
|
64K
|
8
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
1.0K |
543K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
1.0K
|
543K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
TripAces
|
1.0K |
543K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
1.0K
|
543K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
4 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
605
|
273K
|
4
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Comment on research report
|
|
TripAces
|
316 |
164K |
3 |
20/02/24 |
20/02/24 |
ASX - By Stock
|
316
|
164K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
3 |
17/02/24 |
17/02/24 |
ASX - By Stock
|
605
|
273K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Comment on research report
|
|
TripAces
|
316 |
164K |
3 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
316
|
164K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
5 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
605
|
273K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.8M |
5 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
10K
|
4.8M
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.8M |
28 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
10K
|
4.8M
|
28
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
23 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
605
|
273K
|
23
|
|
ASX - By Stock
|
NEU |
Re:
Merck to acquire Prometheus in a US$ 10.8 b deal
|
|
TripAces
|
107 |
62K |
7 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
107
|
62K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
TripAces
|
10K |
4.8M |
21 |
28/01/24 |
28/01/24 |
ASX - By Stock
|
10K
|
4.8M
|
21
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
6 |
25/01/24 |
25/01/24 |
ASX - By Stock
|
605
|
273K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
TripAces
|
605 |
273K |
16 |
25/01/24 |
25/01/24 |
ASX - By Stock
|
605
|
273K
|
16
|
|
ASX - By Stock
|
NEU |
Re:
Jefferies Role
|
|
TripAces
|
9 |
4.4K |
29 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
9
|
4.4K
|
29
|
|